All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Visual abstract | Momelotinib in MF with anemia: Real-world findings
Do you know... In the MOMGEMFIN study, what proportion of transfusion-dependent patients with MF achieved transfusion independence after 3 months of momelotinib treatment?
The efficacy of momelotinib in reducing spleen size, improving symptoms, increasing hemoglobin levels, and reducing transfusion dependency has been demonstrated in several clinical trials in both Janus kinase inhibitor (JAKi)-naïve and JAKi- exposed patients with myelofibrosis (MF).1
This visual abstract summarizes real-world outcomes of momelotinib in patients with MF and anemia from the MOMGEMFIN study, published by Pérez-Lamas et al.1 in Blood Cancer Journal, as well as additional European real-world datasets, including a German retrospective chart review published by Al-Ali et al.2 in the abstract proceedings of the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE.
This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.jpeg&w=3840&q=75)